Patient-derived breast cancer organoids that retain key molecular, histopathological and phenotypic features of human breast tumors, intended for use as in vitro research models for oncology mechanism study, drug discovery and preclinical exploratory research.
- Overview
- Details
- Advantages
- FAQs
Overview
Breast cancer is one of the most prevalent malignant tumors in women globally. Its onset involves cumulative genetic and epigenetic alterations in mammary epithelial cells, progressing from precancerous lesions to invasive carcinoma. Commonly reported molecular alterations include ERBB2 (HER2) amplification, PIK3CA mutation, PTEN copy number loss, BRCA1/2 variants, and dysregulation of estrogen receptor (ER)/progesterone receptor (PR) signaling pathways. Triple-negative breast cancer (TNBC) is a clinically defined subtype with limited targeted therapy options currently available.
Breast tumors exhibit substantial interpatient and intrapatient heterogeneity across multiple molecular subtypes, and conventional 2D cell cultures often show phenotypic drift during long-term passage, reducing their relevance for translational research.
Our breast cancer organoids are derived from patient tumor tissues, and are cultured to maintain the molecular profile and structural features of the source specimens. These three-dimensional models are designed to support basic and preclinical research on breast tumor biology, target exploration and therapeutic response assessment.
Key Phenotypic Features of Breast Cancer Organoids
- Molecular subtype classification consistent with common breast cancer research frameworks
- Expression patterns of ER, PR and HER2 comparable to source tumor tissues
- Preserved genetic alterations including PIK3CA, BRCA1/2 and ESR1 variants
- Mammary glandular-like 3D architecture and typical morphological characteristics
- Enrichment of tumor cell populations with stemness-related marker expression
- Consistent proliferation and signaling pathway activity with parental tumors
- Retained phenotypic diversity across different tumor grades and stages
These features make the organoids suitable for mechanistic studies, biomarker exploration and preclinical drug candidate evaluation in breast cancer research.
Fig. 1. Breast cancer organoid culture and applications (Ebrahimi, et al., 2022).
Our Breast Cancer Organoids
Our breast cancer organoids are cryopreserved, ready-to-use in vitro research models, maintained in defined culture systems to reduce phenotypic variation and support experimental reproducibility.
Core Characteristics
- Subtype coverage: Includes models representing common breast cancer molecular subtypes
- Specimen diversity: Derived from primary tumor tissues of different grades and stages
- Phenotype stability: Optimized culture conditions to minimize spontaneous molecular drift
- Experimental compatibility: Adaptable to standard cell-based assay workflows
- Standardized format: Uniform cryovial specifications for consistent experimental seeding
Characterization & Quality Control
All organoids undergo standardized validation to ensure research utility:
- Genetic profiling: Targeted sequencing of selected breast cancer-associated genes
- Immunophenotyping: Immunostaining validation of ER, PR, HER2 and proliferation markers
- Morphological assessment: Microscopic confirmation of 3D structure and growth status
- Viability testing: Post-thaw recovery rate ≥80% in routine QC batches
- Biosafety verification: Mycoplasma-negative status and identity confirmation
Research Applications
These organoids are suitable for a range of in vitro breast cancer research scenarios:
- Mechanism Research: Study of tumor proliferation, signaling pathways and cellular heterogeneity.
- Preclinical Drug Screening: Evaluation of small molecule compounds, antibody drugs and combination regimens.
- Biomarker Exploration: Identification of potential molecular markers associated with drug response.
- Resistance Study: Modeling of phenotypic changes under sustained drug exposure in vitro.
- Co-culture Models: Optional compatible with stromal cell co-culture for tumor microenvironment research.
Key Strengths
- Research-relevant phenotypes: Retain key molecular and cellular features of source tumors
- Reduced preparation time: Eliminate de novo model establishment steps for researchers
- Batch consistency: Standardized production and QC processes to support reproducible results
- Assay flexibility: Compatible with common molecular and cellular biology assays
- Ethically sourced: All materials obtained under approved informed consent frameworks
FAQs
Q: Are TNBC models included in the current library?
Yes, we maintain a portion of models with TNBC-associated molecular features, available for related research applications upon request.
Q: Are these organoids suitable for immune co-culture assays?
The organoids express MHC molecules and can be used for in vitro co-culture studies with immune cells, subject to user-defined experimental design.
Q: How stable are hormone receptor expressions during passage?
Under recommended culture conditions, hormone receptor expression remains detectable for multiple passages in applicable models, with specific stability data provided per batch.
Q: Can custom models be prepared from specific samples?
We accept collaborative custom model development projects based on available sample types and research requirements, subject to ethical approval and feasibility assessment.
Support your breast cancer research with physiologically relevant, standardized in vitro organoid models.
Contact us to request product specifications, characterization data or discuss custom model collaboration opportunities.
Online Inquiry